Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Jump Financial LLC

Jump Financial LLC grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 351.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 112,816 shares of the biopharmaceutical company's stock after acquiring an additional 87,825 shares during the quarter. Jump Financial LLC owned about 0.12% of Ultragenyx Pharmaceutical worth $4,746,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $35,000. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $42,000. Van ECK Associates Corp increased its position in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 273 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. 97.67% of the stock is owned by institutional investors.

Insider Activity

In related news, CAO Theodore Alan Huizenga sold 967 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the transaction, the chief accounting officer now owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the transaction, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 124,643 shares of company stock valued at $5,256,268 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RARE. Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Wells Fargo & Company lifted their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. JPMorgan Chase & Co. upped their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Trading Up 2.0 %

RARE traded up $0.71 during midday trading on Friday, hitting $35.69. 690,760 shares of the company were exchanged, compared to its average volume of 808,632. The company's 50 day simple moving average is $38.41 and its 200 day simple moving average is $44.26. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -5.63 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.